DE60042968D1 - Zusammensetzungen und methoden zur behandlung lymphoma - Google Patents

Zusammensetzungen und methoden zur behandlung lymphoma

Info

Publication number
DE60042968D1
DE60042968D1 DE60042968T DE60042968T DE60042968D1 DE 60042968 D1 DE60042968 D1 DE 60042968D1 DE 60042968 T DE60042968 T DE 60042968T DE 60042968 T DE60042968 T DE 60042968T DE 60042968 D1 DE60042968 D1 DE 60042968D1
Authority
DE
Germany
Prior art keywords
mol
compositions
methods
cholesterol
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042968T
Other languages
English (en)
Inventor
Andreas H Sarris
Fernando Cabanillas
Patricia M Logan
Clive T Burge
James H Goldie
Murray S Webb
Lawrence D Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hana Biosciences Inc
University of Texas System
Original Assignee
Hana Biosciences Inc
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hana Biosciences Inc, University of Texas System filed Critical Hana Biosciences Inc
Application granted granted Critical
Publication of DE60042968D1 publication Critical patent/DE60042968D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60042968T 1999-04-01 2000-03-31 Zusammensetzungen und methoden zur behandlung lymphoma Expired - Lifetime DE60042968D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (1)

Publication Number Publication Date
DE60042968D1 true DE60042968D1 (de) 2009-10-29

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042968T Expired - Lifetime DE60042968D1 (de) 1999-04-01 2000-03-31 Zusammensetzungen und methoden zur behandlung lymphoma

Country Status (14)

Country Link
EP (3) EP1985285A3 (de)
JP (3) JP2002541088A (de)
AT (1) ATE442839T1 (de)
AU (1) AU777572B2 (de)
BR (1) BRPI0009448B8 (de)
CA (1) CA2366787C (de)
CY (1) CY1109641T1 (de)
DE (1) DE60042968D1 (de)
DK (2) DK1169021T3 (de)
ES (2) ES2333400T3 (de)
HK (1) HK1152246A1 (de)
IL (4) IL145720A0 (de)
PT (1) PT1169021E (de)
WO (1) WO2000059473A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
EP1985285A3 (de) * 1999-04-01 2009-08-12 Hana Biosciences, Inc. Zusammensetzungen und Verfahren zur Behandlung von Lymphomen
EP1229934B1 (de) 1999-10-01 2014-03-05 Immunogen, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2002312777B2 (en) * 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
NZ563281A (en) * 2002-05-17 2009-05-31 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
EP1765399A1 (de) * 2004-07-09 2007-03-28 Schering Aktiengesellschaft Kombinationstherapie mit radioaktiv markiertem anti-cd20-antikörper bei der behandlung von b-zellen-lymphomen
ATE545408T1 (de) * 2004-08-10 2012-03-15 Talon Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von leukämie
EP2200431B1 (de) 2007-09-10 2016-07-20 Boston Biomedical, Inc. Neue zusammensetzungen und verfahren für die bekämpfung von krebs
AR070865A1 (es) 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso
MX2011004344A (es) * 2008-10-24 2011-11-18 Gloucester Pharmaceuticals Terapia contra el cancer.
CN104837483B (zh) * 2012-11-20 2017-09-01 光谱医药公司 制备治疗用途的脂质体封装式长春新碱的改进方法
ES2824074T3 (es) * 2013-01-24 2021-05-11 Memorial Sloan Kettering Cancer Center Método para diagnosticar o tratar tumores mediante el uso de liposomas que contienen esfingomielina
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1985285A3 (de) * 1999-04-01 2009-08-12 Hana Biosciences, Inc. Zusammensetzungen und Verfahren zur Behandlung von Lymphomen

Also Published As

Publication number Publication date
HK1152246A1 (en) 2012-02-24
DK2266537T3 (en) 2014-12-15
IL212390A (en) 2014-08-31
CA2366787C (en) 2013-03-12
ES2333400T3 (es) 2010-02-22
JP2002541088A (ja) 2002-12-03
JP2012158602A (ja) 2012-08-23
WO2000059473A1 (en) 2000-10-12
EP2266537A2 (de) 2010-12-29
EP1985285A2 (de) 2008-10-29
EP1169021B1 (de) 2009-09-16
PT1169021E (pt) 2009-11-18
IL145720A0 (en) 2002-07-25
BRPI0009448B1 (pt) 2018-09-11
JP2015071631A (ja) 2015-04-16
AU777572B2 (en) 2004-10-21
DK1169021T3 (da) 2010-01-11
JP5981214B2 (ja) 2016-08-31
IL212389A (en) 2015-07-30
BR0009448A (pt) 2002-01-08
CY1109641T1 (el) 2014-08-13
ES2524141T3 (es) 2014-12-04
IL145720A (en) 2011-05-31
EP2266537B1 (de) 2014-09-03
IL212390A0 (en) 2011-06-30
BRPI0009448B8 (pt) 2021-05-25
EP2266537A3 (de) 2012-02-22
ATE442839T1 (de) 2009-10-15
CA2366787A1 (en) 2000-10-12
EP1985285A3 (de) 2009-08-12
AU4060600A (en) 2000-10-23
IL212389A0 (en) 2011-06-30
EP1169021A1 (de) 2002-01-09

Similar Documents

Publication Publication Date Title
DE60042968D1 (de) Zusammensetzungen und methoden zur behandlung lymphoma
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
AP1852A (en) '3-Azabicyclo{3.1.0] hexane derivatives as opiate receptors ligands.
ATE284210T1 (de) Verfahren und zusammensetzung zur behandlung von krebs
BR9914167A (pt) Composto, método de tratamento, inibição do crescimento de, ou erradicação de neoplasmas, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e processo para preparar o composto
TR200103525T2 (tr) Bisiklik poliaminosit metal kompleksleri, bunları hazırlamak için yöntem ve bunların tıbbi görüntülemede kullanımı.
ATE295347T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
HK1023064A1 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
DK1200418T3 (da) Nematodicide trifluorbutener
CA2334907A1 (en) Method and composition for inhibiting growth of microorganisms including peracetic acid and a non-oxidizing biocide
IL115920A0 (en) 2,2-dichloroalkanecarboxylic acids process of their production and pharmaceutical agents containing these
SE0104248D0 (sv) Method of treatment
PL338181A1 (en) Novel chemical compounds
WO2004033423A3 (en) Anticancer compounds
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
DE69902999D1 (de) Glucocorticoide zur behandlung von glomerulonephitis
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
ATE283863T1 (de) Verfahren zur herstellung von indolopyrrolocarbazol-derivaten
DE60233353D1 (de) Verfahren zur behandlung von halitose
MY130771A (en) 3-azabicyclo [3.1.0] hexane derivatives useful in therapy.
ATE250078T1 (de) Verfahren zur herstellung von 4,4-dimethyl-5 alpha-cholesta-8,14,24-trien-3 beta-ol und zwischenprodukte im verfahren (i)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1169021

Country of ref document: EP

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER,